<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02931539</url>
  </required_header>
  <id_info>
    <org_study_id>SHP620-303</org_study_id>
    <secondary_id>2015-004725-13</secondary_id>
    <nct_id>NCT02931539</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of maribavir to investigator-assigned
      anti-Cytomegalovirus (CMV) therapy in CMV viremia clearance in transplant recipients who are
      refractory or resistant to prior anti-CMV treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 29, 2016</start_date>
  <completion_date type="Anticipated">September 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 29, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants who Achieve Confirmed Clearance of Plasma CMV DNA (CMV Viremia Clearance) at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Confirmed CMV viremia clearance is defined as plasma CMV DNA concentration less than (&lt;) lower limit of quantification (LLOQ) that is (i.e), &lt;137 International Units per millilitre (IU/mL) when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive postbaseline samples, separated by at least 5 days, regardless of whether either study assigned treatment is discontinued before the end of the stipulated 8 weeks of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Achieve CMV Viremia Clearance and Tissue-invasive CMV Disease or CMV Syndrome Improvement or Resolution</measure>
    <time_frame>Baseline, Week 8, Week 16</time_frame>
    <description>Confirmed CMV viremia clearance is defined as plasma CMV DNA concentration &lt;LLOQ i.e, &lt;137 IU/mL when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive postbaseline samples, separated by at least 5 days. The gold standard for diagnosing CMV tissue invasive disease is the identification of CMV inclusions in the infected cells of the tissues or identification of CMV in biopsy tissue samples. Achievement of CMV viremia clearance and resolution or improvement of tissue-invasive CMV disease or CMV syndrome for participants symptomatic at baseline or achievement of clearance of viremia and no symptoms of tissue invasive CMV disease or CMV syndrome for participants asymptomatic at baseline at the end of Study Week 8, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy, followed by maintenance of this treatment effect (Follow-up Week 16) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Achieve Confirmed Clearance of Plasma CMV DNA (CMV Viremia Clearance) After 8 Weeks of Receiving Study-assigned Treatment</measure>
    <time_frame>Week 8</time_frame>
    <description>Confirmed CMV viremia clearance is defined as plasma CMV DNA concentration &lt;LLOQ i.e, &lt;137 IU/mL when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive postbaseline samples, separated by at least 5 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Achieve CMV Viremia Clearance and CMV infection symptom After 8 Weeks of Receiving Study-assigned Treatment</measure>
    <time_frame>Baseline, Week 8, Week 12, Week 16, Week 20</time_frame>
    <description>Confirmed CMV viremia clearance is defined as plasma CMV DNA concentration &lt;LLOQ i.e, &lt;137 IU/mL when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive post baseline samples, separated by at least 5 days. The gold standard for diagnosing CMV tissue invasive disease is the identification of CMV inclusions in the infected cells of the tissues or identification of CMV in biopsy tissue samples. Achievement of CMV viremia clearance and CMV infection symptom for participants symptomatic at baseline or achievement of clearance of viremia and no symptoms of tissue invasive CMV disease or CMV infection symptom for participants asymptomatic at baseline after receiving 8 weeks of study-assigned treatment, followed by maintenance of this treatment effect through study weeks 12, week 16 and week 20 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Maintain Confirmed CMV Viremia Clearance and CMV Infection Symptom Control</measure>
    <time_frame>Week 8, Week 12 and Week 20</time_frame>
    <description>Proportion of participants who maintain confirmed CMV viremia clearance and CMV infection symptom control, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Recurrence of CMV Viremia</measure>
    <time_frame>Baseline to Week 20</time_frame>
    <description>Recurrence of CMV viremia is defined as plasma CMV DNA concentration &gt;=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Recurrence of CMV Viremia During the First 8 Weeks of the Study</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Recurrence of CMV viremia is defined as plasma CMV DNA concentration &gt;=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Recurrence of CMV Viremia During 12 weeks of the Follow-up Phase</measure>
    <time_frame>Week 8 to Week 20</time_frame>
    <description>Recurrence of CMV viremia is defined as plasma CMV DNA concentration &gt;=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Recurrence of CMV Viremia who Completed 8 Weeks of Study-assigned Treatment</measure>
    <time_frame>Baseline to Week 20</time_frame>
    <description>Recurrence of CMV viremia is defined as plasma CMV DNA concentration &gt;=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Recurrence of CMV Viremia During the First 8 Weeks of the Treatment who Completed 8 Weeks of Study-assigned Treatment</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Recurrence of CMV viremia is defined as plasma CMV DNA concentration &gt;=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Recurrence of CMV Viremia During 12 weeks of the Follow-up Phase who Completed 8 Weeks of Study-assigned Treatment</measure>
    <time_frame>Week 8 to Week 20</time_frame>
    <description>Recurrence of CMV viremia is defined as plasma CMV DNA concentration &gt;=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Recurrence of CMV Viremia While on Study-assigned Treatment</measure>
    <time_frame>Baseline up to termination of study treatment (up to 8 weeks)</time_frame>
    <description>Recurrence of CMV viremia is defined as plasma CMV DNA concentration &gt;=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Recurrence of CMV Viremia in the Period From the Termination of Study Treatment to the End of the Study</measure>
    <time_frame>Termination of Study Treatment to the End of the Study (12 weeks)</time_frame>
    <description>Recurrence of CMV viremia is defined as plasma CMV DNA concentration &gt;=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Develop Maribavir CMV Resistance</measure>
    <time_frame>Baseline to Week 20</time_frame>
    <description>Proportion of participants who develop resistance to maribavir will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Mortality</measure>
    <time_frame>Baseline to week 20</time_frame>
    <description>Mortality will be assessed by the number of participants who died between week 0 to week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Achieve Confirmed Clearance of Plasma CMV DNA (CMV Viremia Clearance) at Week 8 After Starting Maribavir Rescue Treatment</measure>
    <time_frame>From start of maribavir rescue treatment through 8 weeks</time_frame>
    <description>Confirmed CMV viremia clearance is defined as plasma CMV DNA concentration &lt;LLOQ i.e, &lt;137 IU/mL when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive postbaseline samples, separated by at least 5 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Achieve CMV Viremia Clearance and Tissue-invasive Disease or CMV Syndrome Improvement or Resolution After Starting Maribavir Rescue Treatment</measure>
    <time_frame>From start of maribavir rescue treatment through 16 weeks</time_frame>
    <description>Confirmed CMV viremia clearance is defined as plasma CMV DNA concentration &lt;LLOQ i.e, &lt;137 IU/mL when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive postbaseline samples, separated by at least 5 days. The gold standard for diagnosing CMV tissue invasive disease is the identification of CMV inclusions in the infected cells of the tissues or identification of CMV in biopsy tissue samples. Achievement of CMV viremia clearance and resolution or improvement of tissue-invasive CMV disease for participants symptomatic at baseline or achievement of clearance of viremia and no symptoms of tissue invasive CMV disease for participants asymptomatic at baseline after receiving maribavir rescue treatment, followed by maintenance of this treatment effect through study Week 16 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline to Week 20</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant who will receive study drug without regard to possibility of causal relationship. TEAEs are defined as AEs that has a start date on or after the first dose of study treatment or that has a start date before the date of first dose of study treatment, but increases in severity after the first dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose Concentration (Cmin) of Maribavir</measure>
    <time_frame>Predose at Week 1, 4 and 8</time_frame>
    <description>Cmin of Maribavir will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve Over the 12-hour Dosing Interval at Steady State (AUC0-tau)</measure>
    <time_frame>Week 1: Pre-morning dose and 1, 2, 3, 4, 6, 8 and 12 hours post morning dose Week 4: Pre-morning dose Week 8: Pre-morning dose and 2-4 hour post morning dose</time_frame>
    <description>AUC0-tau of Maribavir will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Maribavir</measure>
    <time_frame>Week 1: Pre-morning dose and 1, 2, 3, 4, 6, 8 and 12 hours post morning dose Week 4: Pre-morning dose Week 8: Pre-morning dose and 2-4 hour post morning dose</time_frame>
    <description>Cmax of Maribavir will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time When Maximum Concentration is Observed (Tmax) of Maribavir</measure>
    <time_frame>Week 1: Pre-morning dose and 1, 2, 3, 4, 6, 8 and 12 hours post morning dose Week 4: Pre-morning dose Week 8: Pre-morning dose and 2-4 hour post morning dose</time_frame>
    <description>Tmax of Maribavir will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of Maribavir</measure>
    <time_frame>Week 1: Pre-morning dose and 1, 2, 3, 4, 6, 8 and 12 hours post morning dose Week 4: Pre-morning dose Week 8: Pre-morning dose and 2-4 hour post morning dose</time_frame>
    <description>CL/F of Maribavir will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of Maribavir</measure>
    <time_frame>Week 1: Pre-morning dose and 1, 2, 3, 4, 6, 8 and 12 hours post morning dose Week 4: Pre-morning dose Week 8: Pre-morning dose and 2-4 hour post morning dose</time_frame>
    <description>Vz/F of Maribavir will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">352</enrollment>
  <condition>Cytomegalovirus (CMV)</condition>
  <arm_group>
    <arm_group_label>Maribavir Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 400 milligrams (mg) (2x200 mg tablets) maribavir twice daily orally (doses separated by a minimum of 8 hours) for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigator-Assigned Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive anti-CMV agent best suited to treat the respective participant as per the investigator's prescribed dosing regimen for 8 weeks. Agents of choice include: ganciclovir, valganciclovir, foscarnet, or cidofovir.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maribavir</intervention_name>
    <description>Maribavir 400 milligrams (mg) (2x200 mg tablets) will be administered twice daily for 8 weeks.</description>
    <arm_group_label>Maribavir Treatment</arm_group_label>
    <other_name>SHP620</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
    <description>Ganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.</description>
    <arm_group_label>Investigator-Assigned Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>Valganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.</description>
    <arm_group_label>Investigator-Assigned Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foscarnet</intervention_name>
    <description>Foscarnet as per the investigator's prescribed dosing regimen will be administered for 8 weeks.</description>
    <arm_group_label>Investigator-Assigned Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cidofovir</intervention_name>
    <description>Cidofovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.</description>
    <arm_group_label>Investigator-Assigned Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The participant must be able to provide written, personally signed, and dated informed
             consent to participate in the study before completing any study-related procedures. As
             applicable, a parent/both parents or legally authorized representative (LAR) must
             provide signature of informed consent and there must be documentation of assent by the
             participant before completing any study-related procedures.

          2. The participant must be a recipient of hematopoietic stem cell or solid organ
             transplant.

          3. The participant must have a documented CMV infection in whole blood or plasma, with a
             screening value of greater than or equal to (&gt;=) 2730 international units per
             milliliter (IU/mL) in whole blood or &gt;= 910 IU/mL in plasma in 2 consecutive
             assessments, separated by at least 1 day, as determined by local or central specialty
             laboratory quantitative polymerase chain reaction (qPCR) or comparable quantitative
             CMV DNA results. Both samples should be taken within 14 days prior to randomization
             with second sample obtained within 5 days prior to randomization. The same laboratory
             and same sample type (whole blood or plasma) must be used for these assessments.

          4. The participant must have a current CMV infection that is refractory to the most
             recently administered of the four anti-CMV treatment agents. Refractory is defined as
             documented failure to achieve greater than (&gt;) 1 log10 (common logarithm to base 10)
             decrease in CMV DNA level in whole blood or plasma after a 14 day or longer treatment
             period with intravenous (IV) ganciclovir/oral valganciclovir, IV foscarnet, or IV
             cidofovir.

             a. Participants with documentation of 1 or more CMV genetic mutations associated with
             resistance to ganciclovir/valganciclovir, foscarnet, and/or cidofovir must also meet
             the definition of refractory CMV infection.

          5. The Investigator must be willing to treat the participant with at least one of the
             available anti-CMV drugs (ganciclovir, valganciclovir, foscarnet, or cidofovir). Note:
             Combination therapy with foscarnet and cidofovir is not permitted in the
             investigator-assigned anti-CMV treatment (IAT) arm due to the potential for serious
             nephrotoxicity.

          6. The participant must be &gt;= 12 years of age at the time of consent.

          7. The participant must weigh &gt;= 35 kilogram (kg).

          8. The participant must have all of the following results as part of screening laboratory
             assessments (results from either the central laboratory or a local laboratory can be
             used for qualification):

               1. Absolute neutrophil count (ANC) &gt;= 1000/ millimeter cube (mm^3) (1.0 x 10^9/liter
                  [L])

               2. Platelet count &gt;= 25,000/mm^3 [25 x 10^9/L],

               3. Hemoglobin &gt;= 8 grams per deciliter (g/dL).

               4. Estimated glomerular filtration rate (eGFR) &gt; 30 (milliliters per minute (mL/min)
                  /1.73 square meter (m^2) as assessed by Modification of Diet in Renal Disease
                  (MDRD) formula for participants &gt;= 18 years of age or Schwartz formula for
                  participants less than (&lt;) 18 years of age.

          9. The participant must have a negative serum beta-human chorionic gonadotropin
             (beta-HCG) pregnancy test at screening, if a female of child bearing potential.
             Additional urine pregnancy tests may be done per institutional requirements. Sexually
             active females of child bearing potential must agree to comply with any applicable
             contraceptive requirements of the protocol. If male, must agree to use an acceptable
             method of birth control, as defined in the protocol, during the study treatment
             administration period and for 90 days afterward if treated with maribavir,
             ganciclovir, valganciclovir, or cidofovir and for 180 days afterward if treated with
             foscarnet.

         10. The participant must be able to swallow tablets, or receive tablets crushed and/or
             dispensed in water via nasogastric or orogastric tube.

         11. The participant must be willing and have an understanding and ability to fully comply
             with study procedures and restrictions defined in the protocol.

         12. The participant must be willing to provide necessary samples (example [e.g,] biopsy)
             for the diagnosis of tissue invasive CMV disease at baseline as determined by the
             Investigator.

         13. The participant must have a life expectancy of &gt;= 8 weeks.

        Exclusion Criteria:

          1. Have a current CMV infection that is considered refractory or resistant due to
             inadequate adherence to prior anti-CMV treatment, to the best knowledge of the
             Investigator.

          2. Require ganciclovir, valganciclovir, foscarnet, or cidofovir administration for
             conditions other than CMV when study treatment is initiated (example: herpes simplex
             virus (HSV) coinfection requiring use of any of these agents after the randomization)
             or would need a coadministration with maribavir for CMV infection. NOTE: A participant
             who is not continuing with the same anti-CMV drug(s) (ganciclovir, valganciclovir or
             foscarnet) for the study treatment (if randomized to the investigator assigned
             anti-CMV treatment arm), must discontinue their use before the first dose of study
             drug. If participant is currently being treated with cidofovir and is assigned another
             anti-CMV therapy by the investigator, the participant must discontinue its use at
             least 14 days prior to randomization at Visit 2/Day 0 and the first dose of study
             treatment.

          3. Be receiving leflunomide, letermovir, or artesunate when study treatment is initiated.
             NOTE: Participants receiving leflunomide must discontinue the use at least 14 days
             prior to randomization at Visit 2/Day 0 and the first dose of study treatment.
             Participants receiving letermovir must discontinue use at least 3 days prior to the
             first dose of study treatment. Participants receiving artesunate must discontinue the
             use prior to the first dose of study treatment.

          4. Have severe vomiting, diarrhea, or other severe gastrointestinal illness within 24
             hours prior to the first dose of study treatment that would preclude administration of
             oral/enteral medication.

          5. Have known hypersensitivity to the active substance or to an excipient for a study
             treatment.

          6. Have tissue invasive CMV disease with central nervous system involvement including the
             retina (example, CMV retinitis).

          7. Have serum aspartate aminotransferase (AST) &gt; 5 times upper limit of normal (ULN) at
             screening, or serum alanine aminotransferase (ALT) &gt; 5 times ULN at screening, or
             total bilirubin &gt;= 3.0 x ULN at screening (except for documented Gilbert's syndrome),
             by local or central lab. Participants with biopsy confirmed CMV hepatitis will not be
             excluded from study participation despite AST or ALT &gt; 5 times ULN at screening.

          8. Have known positive results for human immunodeficiency virus (HIV). Participants must
             have a confirmed negative HIV test result within 3 months of study entry or, if
             unavailable, be tested by a local laboratory during the screening period.

          9. Require mechanical ventilation or vasopressors for hemodynamic support at the time of
             enrollment.

         10. Be female and pregnant or breast feeding.

         11. Have previously received maribavir.

         12. Have received any investigational agent with known anti-CMV activity within 30 days
             before initiation of study treatment or investigational CMV vaccine at any time.

         13. Have received any unapproved agent or device within 30 days before initiation of study
             treatment.

         14. Have active malignancy with the exception of nonmelanoma skin cancer. Participants who
             have had a hematopoietic stem cell transplant (HSCT) and who experience relapse or
             progression of the malignancy as per investigator's opinion are not to be enrolled.

         15. Be undergoing treatment for acute or chronic hepatitis C.

         16. Have any clinically significant medical or surgical condition that, in the
             investigator's opinion, could interfere with the interpretation of study results,
             contraindicate the administration of the assigned study treatment, or compromise the
             safety or well-being of the participant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AdventHealth</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Feinberg School of Medicine Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - PPDS</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>59905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-5400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital - Weill-Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710-4000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center - PIN</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina - PPDS</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor All Saints Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2348</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center - PPDS</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Health, Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Washington</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tiroler Landeskrankenanstalten GmbH</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <state>Brussels</state>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan AV</name>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Center Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital</name>
      <address>
        <city>København Ø</city>
        <state>Capital</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Brest - Hospital Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <state>Finistère</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Rangueil</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <state>Hauts-de-Seine</state>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Rennes</name>
      <address>
        <city>Rennes</city>
        <state>Ille-et-Vilaine</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Bretonneau</name>
      <address>
        <city>Tours</city>
        <state>Indre-et-Loire</state>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Nantes</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <state>Rhône</state>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-bénite</city>
        <state>Rhône</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <state>Val-de-Marne</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-Marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Hôpital Sud</name>
      <address>
        <city>AMIENS Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de GRENOBLE</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Poitiers La Miletrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de la Loire</name>
      <address>
        <city>Saint-Priest en Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Civil</name>
      <address>
        <city>STRASBOURG Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Heidelberg - PPDS</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Heidelberg - PPDS</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele S.r.l. - PPDS</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo Di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona-Umberto I G.M. Lancisi G. Salesi</name>
      <address>
        <city>Ancona</city>
        <state>Marche</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56216</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine</name>
      <address>
        <city>Udine</city>
        <zip>12345</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital (SGH)</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacio Puigvert</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Salamanca - H. Clinico</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud (fr)</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Coventry</name>
      <address>
        <city>Coventry</city>
        <state>Birmingham</state>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>West Midlands</city>
        <state>Birmingham</state>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre - PPDS</name>
      <address>
        <city>Glasgow</city>
        <state>Glasgow City</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital - PPDS</name>
      <address>
        <city>Wythenshawe</city>
        <state>Manchester</state>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Childrens Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>Yorkshire</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool and Broadgreen University Hospitals NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary - PPDS</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>October 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2016</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Cidofovir</mesh_term>
    <mesh_term>Foscarnet</mesh_term>
    <mesh_term>Maribavir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

